美国 · 平台与数据 · TipRanks
Cantargia Reports Early Nadunolimab Responses in MDS and AML
Nadunolimab combinations produced responses in MDS and AML. Limited treatment-related severe toxicity supported nadunolimab’s early profile. Looking for the best stocks to buy?…
在 TipRanks 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.tipranks.com)




